Overview

Safety of Exercise and High-dose Salbutamol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Receiving Therapeutic Doses of Indacaterol (QAB 149) and Salmeterol

Status:
Completed

Trial end date:
2008-06-01

Target enrollment:

Participant gender:

Summary

This study investigated the effect of exercise and high-dose salbutamol on the maximum heart rate in patients with chronic obstructive pulmonary disease (COPD) receiving therapeutic doses of indacaterol, salmeterol and placebo.

Phase:

Phase 2

Details

Lead Sponsor:

Novartis

Treatments:

Albuterol
Salmeterol Xinafoate